MAPT and Alzheimer disease: We examined the frequency of CERAD scores in our GT-38 defined Braak AD-tau stages and found an increased frequency of patients with high plaque burden (CERAD C2/3) among those patients with Braak AD-tau B2/3 compared to those with low Braak B0/1 (χ2(1, n=165)=17.76; p < 0.001).